Published studies investigating the role of APOE gene on lipid response (total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides) to statin treatment have reported inconsistent results. A meta-analysis was conducted to estimate the lipid response to statin treatment among APOE genetic variants (e2 carriers, e3e3 homozygotes and e4 carriers). Twenty-four studies were included in the meta-analyses. The pooled mean reduction (Dm) in TC from baseline was significant for all variants (e2 carriers: Dm ¼ À27.7% (À32.5 to À22.8%), e3e3: Dm ¼ À25.3% (À28.0 to À22.6%) and e4 carriers: Dm ¼ À25.1% (À29.3 to À21.0%)). Significant changes in LDL-C, HDL-C and triglyceride levels were also noted for all genotypes, although these changes did not differ significantly among genotypic groups. There was significant heterogeneity among the studies. Given these non-significant effects of APOE genotypes on lipid responses, there is little reason to consider the use of APOE genetic testing for guiding treatment with statins.
Introduction
Statins are among the most widely prescribed classes of drugs worldwide. Large clinical trials have established the beneficial effects of statin treatment in primary and secondary prevention of cardiovascular disease. 1 However, considerable interindividual variation exists in response to statin therapy, in terms of lipid responses or clinical outcomes. 2, 3 Important factors in interpreting this variability include the patient's overall health, prognosis, disease severity, quality of drug prescribing, compliance with prescribed pharmacotherapy and the genetic profile of the patient. 4 The search for genetic determinants of treatmenteffect heterogeneity has included more than 40 different genes involved in the pharmacokinetic and pharmacodynamic pathways of statin metabolism. 2, 3 Among the most extensively studied pharmacodynamic genes is the APOE gene, encoding Apolipoprotein E. Apo E is a constituent of triglyceride-rich chylomicrons, very low-density lipoprotein particles, intermediate-density lipoproteins and a subclass of high-density lipoprotein cholesterol (HDL-C). Three major Apolipoprotein E isoforms are coded by three alleles at the APOE gene, designated as e2, e3 and e4 (dbSNP accession numbers, rs7412 and rs429358). The most common allele is e3, which is found in more than half of the general population. 5 Compared with e3 homozygotes, carriers of the e2 allele have lower circulating total cholesterol (TC) levels and higher triglyceride levels, whereas carriers of the e4 allele seem to have higher plasma levels of TC and low-density lipoprotein cholesterol (LDL-C). These differences in lipid levels translate to an increased risk for coronary artery disease among e4 carriers than the other two groups. 6 The potential modifying role of APOE gene on lipid response to statin treatment has been investigated by numerous studies. However, the available evidence published to date is weak, owing to inconsistent and inconclusive results of individual studies. Differential interpretation of these results among investigators has led to the publication of contradictory consensus statements regarding the role of e2 and e4 alleles in determination of statin effect. 2, 3 By considering all available studies in a metaanalysis, our study aims to decrease the uncertainty of the estimated effect size of APOE genetic variants on lipid response to statin treatment and to provide more conclusive evidence regarding the clinical relevance of this proposed pharmacogenetic association.
Results

Eligible studies
The literature review identified 262 titles in PubMed that met the search criteria. Data from 24 studies published in 20 articles that investigated the association between APOE genotypes and statin therapy met the inclusion criteria. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Two articles provided separate data for gender or statin dose. 15, 24 Figure 1 presents a flowchart of retrieved and excluded studies, with the reasons for exclusion. The studies were published between 1999 and 2007. Table 1 lists the number of studies, number of participants, patient and disease characteristics, and study designs. Eighteen studies examined four lipid responses (changes in TC, LDL-C, HDL-C and triglycerides) and the remaining studies reported data on one or more lipid responses. Overall, the meta-analysis included 2848 patients for testing the association of APOE genotype and TC levels after statin therapy.
Among all APOE genotype groups, treatment with statins resulted in statistically significant changes in lipid response from baseline levels (TC in 18 studies, LDL-C in 21 studies, HDL-C in two studies and triglycerides in 11 studies). The remaining studies (15 for TC, 14 for LDL-C, 17 for HDL-C and 19 for triglycerides) reported no difference in lipid response from baseline levels between the genotype groups. E2 carriers had greater reductions in four studies of TC, six studies of LDL-C, three studies of HDL-C and triglyceride levels, respectively, than other genotypes. Tables 2-5 show the results of the main and subgroup analyses for the association between APOE genotypes and mean change in TC, LDL-C, HDL-C and triglyceride levels after statin therapy, respectively. Figure 2 shows the individual and pooled estimates of per cent change in LDL-C from baseline for e2 carriers, e3e3 homozygotes and e4 carriers treated with statins.
Meta-analysis main results and subgroup analysis
Total cholesterol
The pooled change in TC from baseline was significant (Dm ¼ À27.7% (À32.5 to À22.8%), Dm ¼ À25.3% (À28.0 to À22.6%) and Dm ¼ À25.1% (À29.3 to À21.0%). Overall, there was significant and large heterogeneity between the studies (P Q o0.10, I
2 X75%). In subgroup analysis, the reduction in TC remained significant for each genotype subgroups. Comparisons between the genotypic groups for changes in TC from baseline found no statistical difference (PcX0.05), although e2 carriers showed a better response, followed by e3e3 homozygotes and e4 carriers. The presence of familial hyperlipidemia and the use of pravastatin were associated with an attenuated response among e4 carriers than e3e3 homozygotes.
Low-density lipoprotein
The pooled reduction in LDL-C was statistically significant for all genotypic groups (for e2 carriers: Dm ¼ À37.1% (À41.3 to À32.9%), for e3e3 homozygotes: Dm ¼ À34.6 (À38.0 to À31.2%) and for e4 carriers: Dm ¼ À32.7% (À36.7 to À28.7%)). The main analysis revealed significant and large heterogeneity (P Q o0.10, I 2 X50%). Overall, there was no statistically significant difference between the genotypes (PcX0.05). The pattern of results was similar to the reductions in TC: e2 carriers showed a trend for greater reductions, followed by the e3 homozygotes and then the e4 carriers. All investigated subgroups had significant reductions in LDL-C for each genotype. Comparisons between genotypes in subgroup analysis remained nonsignificant, except for the use of atorvastatin, where e4 carriers had statistically significant reductions in LDL-C than e3e3 homozygotes (Pc ¼ 0.04).
High-density lipoprotein
The main analysis for e2 carriers, e3e3 homozygotes and e4 carriers showed great heterogeneity among the studies (Po0.10, I 2 X50%), and the pooled mean increase in HDL-C after statin therapy was significant in all genotypic groups: Dm ¼ þ 9.44% (3.91-15.0%), Dm ¼ þ 7.45% (5.59-9.49%) and Dm ¼ þ 7.61% (4.47-10.7%). Increase in HDL-C levels with statin therapy was greatest in e2 carriers, followed by the e4 carriers and then by e3e3 homozygotes. However, these increases did not differ significantly among the three genotypes. In subgroup analysis by the types of statin, lovastatin and simvastatin, produced significant change in HDL-C for each genotype, whereas pravastatin and atorvastatin showed significant changes only for e3e3 homozygotes 
(P Q 40.14, I 2 o55%). The random effects mean change (Dm) from baseline in total cholesterol (%) and the respective 95% confidence interval (CI) are shown. Significant and large heterogeneity (P Q o0.10, I
2 X50%) is presented in all settings, otherwise, it is indicated in the footnote of the table. The significant differences (Pc-value) between e3e3 homozygotes and the rest genetic contrasts are shown. 
The random effects mean change (Dm) from baseline in LDL-C (%) and the respective 95% confidence interval (CI) are shown. Significant and large heterogeneity (P Q o0.10, I 2 X50%) is presented in all settings, otherwise, it is indicated in the footnote of the table. The significant differences (Pc-value) between e3e3 homozygotes and the rest genetic contrasts are shown.
Response to statin therapy among APOE genetic variants E Zintzaras et al and e4 carriers, respectively. Among the users of atorvastatin, e4 carriers had statistically increases in HDL-C than the other genotypes (Pco0.01). In Asians, changes from baseline levels of HDL-C was not significant in e3e3 homozygotes, whereas e4 carriers had a better response (Pco0.01) after statin therapy. This beneficial effect of the statin therapy was also evident among e4 carriers in diabetics (Pco0.01). Abbreviation: ns, non-significant.
The random effects mean change (Dm) from baseline in HDL-C (%) and the respective 95% confidence interval (CI) are shown. Significant and large heterogeneity (P Q o0.10, I
2 X50%) is presented in all settings, otherwise, it is indicated in the footnote of the table. The significant differences (Pc-value) between e3e3 homozygotes and the rest genetic contrasts are shown. ns ¼ non-significant mean change. The random effects mean change (Dm) from baseline in triglyceride (%) and the respective 95% confidence interval (CI) are shown. Significant and large heterogeneity (P Q o0.10, I 2 X50%) is presented in all settings. The significant differences (Pc-value) between e3e3 homozygotes and the rest genetic contrasts are shown. ns ¼ nonsignificant mean change.
Response to statin therapy among APOE genetic variants E Zintzaras et al Triglycerides
The percentage reduction in the pooled mean triglyceride levels was significant: Dm ¼ À15.6%. (À19.5 to À11.7%), Dm ¼ À12.1% (À15.4 to À8.77%) and Dm ¼ À13.3% (À15.9 to À10.7%), for e2 carriers, e3e3 homozygotes and e4 carriers, respectively after statin therapy. The main analysis showed substantial heterogeneity between the studies (Po0.10, I 2 X50%) Overall, the genotypes did not differ significantly (PcX0.05), although a better response was observed for e2 carriers. The comparisons among genotypes did not yield significant results in subgroup analyses, except for the male gender, which showed a significantly greater reduction in triglyceride levels for e2 carriers (Pco0.01) than other genotypes (Table 5) .
Bias leading to heterogeneity
The meta-regression indicated that baseline lipid levels (TC, LDL-C, HDL-C and triglycerides) had a significant effect 
Baseline comparisons
The baseline measurement for TC, LDL-C, HDL-C and triglycerides were not significantly different among the three genotypes (P ¼ 0.41, P ¼ 0.91, P ¼ 0.97 and P ¼ 0.91).
Discussion
Our meta-analyses indicates that the pooled change from baseline in TC and LDL-C after statin therapy was lower for all genotypic groups (e2 carriers, e3e3 homozygotes and e4 carriers) but without significant difference among groups. However, this analysis also found significant between-study heterogeneity and the results warrant a cautious interpretation. Heterogeneity may stem from a series of factors, including heterogeneity of enrolled cases, genotyping errors, limited statistical power, different study designs and variable interventions (in terms of type, dose, duration or timing). In our subgroup analysis, we explored the possible effects of patient-, disease-or study design-related factors. Although only a few studies were available for certain subgroups (for example, diabetes, Asians, atorvastatin and simvastatin), some factors influencing associations of APOE genotypes and lipid responses with statin therapy include: ethnicity, gender, presence of familial hyperlipidemia, the type of statin used and possibly the presence of diabetes. The heterogeneity may be explained by the interaction of these factors with APOE genotypes in their response to statin therapy as well as by the baseline effect on the relative change in lipid outcomes after statin therapy. As baseline lipid levels predicted response to statins and given that the baseline lipid levels were not significantly different among the genotypic groups, the negative conclusions of the metaanalysis are further justified. Despite the lack of statistical significance, the main analysis for TC and LDL-C responses showed that e2 carriers had a trend for a better response to statin therapy, with a greater pooled point estimate than that of the e3e3 homozygotes and e4 carriers. In a large replication study with a sample size similar to the number of patients included in our meta-analysis, and with a more homogeneous population and intervention (ACCESS), e2 carriers had reductions in LDL-C by 3.5% (Po0.01) over other groups after atorvastatin therapy. 27 The direction and magnitude of this effect is similar to our findings and further support the association between the APOE genotype and the LDL-C lowering response to statin therapy. Another variant in the APOE locus designated as SNP17 was also found to be significant in modifying the response to LDL-C reduction in a large cohort from the pravastatin inflammation/CRP evaluation (PRINCE) trial. 26 Although these effects are small, they could have important implications to affect health on a population basis. Intervention studies with statins in the general population have shown that for every 1% reduction in LDL-C level, there is a 1% reduction in cardiovascular event rates. 2 Genetic meta-analyses have been criticized for lack of consistency in selecting genotypes. In practice, it is not easy to define a priori the proper, biologically meaningful genotype comparisons, because the actual inheritance models are unknown. 29, 30 Early work in the candidate gene era suggests that associations on the basis of highly selected genotype comparisons are almost 10 times more likely to be refuted than other associations. 31 In our analysis, the choice of the genetic contrast was driven by the unavailability of data for separate genotypic groups.
Another major limitation of our analysis is that we included studies with significant diversity in terms of clinical diagnosis, comorbidities, polypharmacy and intervention (type, dosage and duration of statin treatment). Although methodologies for analyses adjusted for the relative efficacy of each type of statin have been proposed, 32 this approach was not feasible in our study. The majority of studies included more than one type or dosage of statin.
Future analyses with more studies of homogeneous groups, with strict inclusion criteria, standardized definitions of phenotypes and responses to therapy may alter the current findings. More efficient strategies, such as haplotype analysis and investigation of epistatic and gene-environment interactions are crucial in the elucidation of complex phenotypes as is the response to statin treatment. Moreover, if researchers can make their data on individual patients readily available, adjusted estimates for the effects of modifiers (such as age) can also be analyzed.
In addition to lipid responses, important phenotypes in pharmacogenomic investigations of statin treatment include clinical outcomes, such as prevention of acute coronary syndromes or serious adverse events such as myositis. Recent findings from the first genome-wide association in the field revealed a strong association between statin-induced myopathy and a previously suspected candidate gene. 33 These findings reinforce the significance of a comprehensive and rational investigation of genes involved in the pharmacokinetic and pharmacodynamic pathways of statin metabolism.
In conclusion, our study revealed non-significant effects of APOE genotypes on the lipid responses after treatment with statins. Although e2 carriers showed a trend towards better responses for all classes of lipids compared with the other genotypic groups, as previously proposed in the literature, these results were not statistically significant. However, studies that investigated the clinical outcomes (mortality or composite cardiovascular events) showed significant benefit from statin treatment irrespective of APOE genotype effect. 7, 34, 35 In view of these results, the APOE genotype and statin treatment interactions do not reproducibly explain a clinically relevant amount of treatment response variability needed to justify implementation of a pharmacogenetic test before initiation of treatment. Until data from rigorous pharmacogenomic investigations provide solid evidence regarding the role of genetic variants in predicting statin efficacy and toxicity, there is little reason
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Materials and methods
Meta-analysis methods Identification and eligibility of relevant studies. All studies published before September 2008 were identified by extended computer-based searches of PubMed. The following search strategy was used: (Apolipoprotein-E OR APOE OR APOE2 OR APOE3 OR APOE4) AND (statin OR hydroxymethylglutaryl-CoA reductase inhibitors OR lovastatin OR atorvastatin OR simvastatin OR pravastatin OR rosuvastatin OR fluvastatin).
Study eligibility criteria included peer-reviewed reports of any study designs (randomized controlled trials, prospective and retrospective cohort, case-control and cross-sectional designs) that included at least 20 human participants and evaluated the lipid response to statin therapy among APOE genotypes. Studies using standard genotyping methods were included. Case reports, editorials and review articles were excluded. Non-English articles were also excluded. Abstracts of retrieved studies were independently read by two investigators (GK, EZ) to assess their appropriateness for this study. The results were compared and disagreements were resolved by consensus. Full-text articles of the studies were evaluated according to the inclusion criteria. All references cited in the studies were also reviewed to identify additional published work not indexed by the searched databases. Duplicate reports or multiple publications of the same article were identified by comparing authors and study recruitment center. Studies were included only once, except when duplicate reports of the same study provided complementary information.
Pharmacogenetic studies providing information on the average change (with the respective variability) (mean± standard error) in lipid levels from baseline after statin treatment for APOE genotypes (e2 carriers, e3 homozygotes or e4 carriers) were included in the meta-analyses. The outcomes relevant to lipid levels included: TC, LDL-C, HDL-C and triglycerides. In studies with overlapping cases or controls, the most recent and/or the largest in size study with extractable data was included in the meta-analysis. The analysis was limited to studies of unrelated people.
Data extraction. From each study, the following information was extracted: first author, publication year, country, setting, study design, eligibility criteria, subject characteristics, details of genotyping methodology, therapy used and co-medications, definitions of outcomes, and baseline and final results for outcomes of interest. Data were extracted for time points as reported in individual studies. A single reviewer extracted data that were verified by a second reviewer. Disagreements were resolved through consensus.
Data synthesis and analysis. Meta-analysis examined whether there was an association between APOE genotypes and improved patient outcomes after therapeutic management with statins. Three genotypic groups were defined as 6 e2 carriers, participants with the e2e2 and e2e3 genotypes; e3e3 homozygotes; and e4 carriers, participants with the e3e4 and e4e4 genotypes. Participants with the e2e4 genotype were excluded because of the hypothesized competing effects of these alleles. 6 The change in lipid levels as per cent improvement (or decline) from baseline for each genotype within a study ((final valueÀbaseline value)/ baseline value) Â 100%) was calculated. Then, the metaanalysis was carried out on the per cent mean change in lipid levels (Dm, (95% confidence interval)) for e2 carriers, e3 homozygotes and e4 carriers, using the inverse of the variance of Dm as a weighting factor. e3e3 homozygotes were used as the reference group for all comparisons.
The pooled changes in lipid levels were estimated using the random effects model. 36 The random effects model assigns a weight to each study based both on the individual study variance and the between-study heterogeneity.
The heterogeneity between studies was tested using the Q-statistic. 30, 37 If Po0.10, then heterogeneity was considered statistically significant. Heterogeneity was quantified with the I 2 metric, which is independent of the number of studies in the meta-analysis. I 2 was calculated for more than two studies. I
2 takes values between 0 and 100% with higher values denoting greater degree of heterogeneity. 30 The meta-analysis consisted of the main (overall) analysis, which includes all the available data and subgroup analysis. Subgroup analysis was used to evaluate patient-and diseaserelated factors that may affect the response to statins, and to explain possible sources of heterogeneity. Subgroup analysis was carried out by patient-related factors (ethnicity, gender), disease-related factors (diabetes mellitus, familial hyperlipidemia) and study design-related factors (duration of follow-up: short follow-up (p12 weeks) and long follow-up (412 weeks)).
Overall, for each outcome, the genotypes were compared using a general linear model under a random-effects assumption and the inverse of the variance of Dm as a weighting factor. In subgroup analysis, the genotypes were compared with z-scores because the number of studies was limited. 38 Significance levels for the comparisons (Pc-value) were adjusted using Bonferroni's correction.
For the main analysis, a meta-regression procedure was adopted to investigate the dependence of the response to therapy on the effect of baseline lipid levels of each study. 39 A differential magnitude of effect in large versus small studies was checked using the Egger regression test 40 and the Begg-Mazumdar test, which is based on Kendall's tau. 41 Given that these tests are underpowered, a differential magnitude of effect in large versus small studies were considered statistically significant at Po0.10.
30
The effect of genotype in baseline measurements was tested using a general lineal model with the baseline measurement as response and the genotype as fixed effect and the study as random effect. Individual genotypes were compared using a post hoc test with Bonferroni's correction.
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